Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CNTX Context Therapeutics	$0.91 +10.5%	$0.66	$0.49 ▼ $2.75	$81.80M	1.88	276,072 shs	321,339 shs
NBTX Nanobiotix	$5.32 +1.8%	$4.47	$2.76 ▼ $6.00	$250.50M	0.41	15,356 shs	4,408 shs
PRQR ProQR Therapeutics	$2.40 +2.1%	$1.91	$1.07 ▼ $4.62	$252.50M	0.36	659,007 shs	161,703 shs
SLRN Acelyrin	$2.27	$2.27	$1.85 ▼ $7.25	$229.17M	1.07	1.28 million shs	N/A

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CNTX Context Therapeutics	+12.23%	+30.57%	+35.39%	-2.12%	-62.32%
NBTX Nanobiotix	+0.09%	-0.94%	+6.12%	+58.38%	-4.51%
PRQR ProQR Therapeutics	-0.42%	+2.17%	+23.68%	+106.14%	+25.00%
SLRN Acelyrin	0.00%	0.00%	0.00%	+3.18%	-67.85%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CNTX Context Therapeutics	3.3423 of 5 stars	3.6	3.0	0.0	0.0	3.3	1.7	1.3
NBTX Nanobiotix	2.6598 of 5 stars	3.3	5.0	0.0	0.0	2.7	0.0	0.6
PRQR ProQR Therapeutics	2.5868 of 5 stars	3.6	5.0	0.0	0.0	2.7	0.0	0.0
SLRN Acelyrin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CNTX Context Therapeutics	3.17	Buy	$5.50	503.14% Upside
NBTX Nanobiotix	2.50	Moderate Buy	$8.00	50.52% Upside
PRQR ProQR Therapeutics	3.13	Buy	$8.00	233.33% Upside
SLRN Acelyrin	2.40	Hold	$9.60	322.91% Upside

Current Analyst Ratings Breakdown

Latest CNTX, NBTX, PRQR, and SLRN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/11/2025	PRQR ProQR Therapeutics	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
6/27/2025	PRQR ProQR Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$8.00
6/27/2025	PRQR ProQR Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$8.00
6/26/2025	CNTX Context Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$4.50 ➝ $4.00
5/13/2025	PRQR ProQR Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$15.00 ➝ $9.00
5/8/2025	CNTX Context Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00 ➝ $9.00
4/29/2025	CNTX Context Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
4/29/2025	CNTX Context Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00 ➝ $9.00
4/29/2025	PRQR ProQR Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$8.00
4/29/2025	PRQR ProQR Therapeutics	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$5.00
4/21/2025	CNTX Context Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform

(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CNTX Context Therapeutics	N/A	N/A	N/A	N/A	$1.27 per share	N/A
NBTX Nanobiotix	$39.18M	6.39	N/A	N/A	($1.51) per share	-3.52
PRQR ProQR Therapeutics	$20.46M	12.34	N/A	N/A	$0.91 per share	2.64
SLRN Acelyrin	N/A	N/A	N/A	N/A	$6.74 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CNTX Context Therapeutics	-$26.73M	-$0.31	N/A	N/A	N/A	N/A	-29.78%	-29.08%	8/6/2025 (Estimated)
NBTX Nanobiotix	-$73.73M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	9/16/2025 (Estimated)
PRQR ProQR Therapeutics	-$30.04M	-$0.35	N/A	N/A	N/A	-157.04%	-53.49%	-22.07%	8/4/2025 (Estimated)
SLRN Acelyrin	-$381.64M	-$2.69	N/A	N/A	N/A	N/A	-44.12%	-39.02%	8/12/2025 (Estimated)

Latest CNTX, NBTX, PRQR, and SLRN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	PRQR ProQR Therapeutics	-$0.08	N/A	N/A	N/A	N/A	N/A
8/12/2025	Q2 2025	SLRN Acelyrin	-$0.71	N/A	N/A	N/A	N/A	N/A
8/6/2025	Q1 2025	CNTX Context Therapeutics	-$0.06	N/A	N/A	N/A	N/A	N/A
5/14/2025	Q1 2025	CNTX Context Therapeutics	-$0.05	-$0.05	N/A	-$0.05	N/A	N/A
5/14/2025	Q1 2025	SLRN Acelyrin	-$0.95	-$0.55	+$0.40	-$0.55	N/A	N/A
5/8/2025	Q1 2025	PRQR ProQR Therapeutics	-$0.09	-$0.1082	-$0.0182	-$0.11	$4.90 million	$4.89 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CNTX Context Therapeutics	N/A	N/A	N/A	N/A	N/A
NBTX Nanobiotix	N/A	N/A	N/A	N/A	N/A
PRQR ProQR Therapeutics	N/A	N/A	N/A	N/A	N/A
SLRN Acelyrin	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CNTX Context Therapeutics	N/A	48.81	48.81
NBTX Nanobiotix	N/A	1.04	1.04
PRQR ProQR Therapeutics	N/A	4.10	4.10
SLRN Acelyrin	N/A	7.15	7.15

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CNTX Context Therapeutics	14.03%
NBTX Nanobiotix	38.81%
PRQR ProQR Therapeutics	32.65%
SLRN Acelyrin	87.31%

Insider Ownership

Company	Insider Ownership
CNTX Context Therapeutics	2.80%
NBTX Nanobiotix	3.45%
PRQR ProQR Therapeutics	8.40%
SLRN Acelyrin	13.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CNTX Context Therapeutics	7	89.70 million	87.19 million	Not Optionable
NBTX Nanobiotix	100	47.13 million	45.51 million	Not Optionable
PRQR ProQR Therapeutics	180	105.21 million	96.38 million	Optionable
SLRN Acelyrin	135	100.95 million	86.68 million	Optionable

CNTX, NBTX, PRQR, and SLRN Headlines

Recent News About These Companies

ACELYRIN Stockholders Approve Merger with Alumis to Create Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases

May 13, 2025 | globenewswire.com

Leading Independent Proxy Advisory Firm ISS Recommends ACELYRIN Stockholders Vote “FOR” the Proposed Transaction with Alumis

May 6, 2025 | globenewswire.com

Acelyrin urges stockholders to vote for proposed merger with Alumis

May 2, 2025 | finance.yahoo.com

ACELYRIN Reiterates Benefits of Value-Maximizing Combination with Alumis

May 1, 2025 | globenewswire.com

Alumis and ACELYRIN Announce Amended Merger Agreement

April 21, 2025 | globenewswire.com

ACELYRIN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acelyrin, Inc. - SLRN

April 16, 2025 | businesswire.com

Alumis Inc.; ACELYRIN, INC.: Alumis and ACELYRIN File Joint Definitive Proxy Statement for Proposed Merger

April 5, 2025 | finanznachrichten.de

Alumis Inc. and ACELYRIN, INC. File Joint Definitive Proxy Statement for Proposed Merger

April 5, 2025 | finanznachrichten.de

STOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating The Merger - SLRN, TURN, BHLB, MHLD

March 30, 2025 | morningstar.comM

Insider Selling: Acelyrin, Inc. (NASDAQ:SLRN) Insider Sells 3,913 Shares of Stock

March 20, 2025 | insidertrades.com

Acelyrin, Inc. (SLRN): One of the Best Short-Term Stocks to Buy Right Now

March 18, 2025 | msn.com

ACELYRIN Adopts Limited-Duration Stockholder Rights Plan

March 13, 2025 | globenewswire.com

Acelyrin: Potential Buyout Led By Concentra Biosciences

March 12, 2025 | seekingalpha.com

Is Acelyrin, Inc. (SLRN) the Best Micro Cap Stock to Buy Now?

March 7, 2025 | insidermonkey.com

ACELYRIN, INC.: ACELYRIN and Alumis Reaffirm Strategic and Financial Rationale of Proposed Merger

March 4, 2025 | finanznachrichten.de

Acelyrin says Concentra indication not expected to result in superior proposal

March 4, 2025 | markets.businessinsider.com

Acelyrin falls as Acelyrin reaffirms deal commitment

March 4, 2025 | msn.com

Acelyrin, Alumis reaffirm strategic, financial rationale of proposed merger

March 4, 2025 | markets.businessinsider.com

ACELYRIN and Alumis Reaffirm Strategic and Financial Rationale of Proposed Merger

March 4, 2025 | globenewswire.com

ACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not Reasonably Expected to Result in a Superior Proposal to Planned Alumis Merger

March 4, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CNTX, NBTX, PRQR, and SLRN Company Descriptions

Context Therapeutics NASDAQ:CNTX

$0.91 +0.09 (+10.51%)

Closing price 04:00 PM Eastern

Extended Trading

$0.93 +0.02 (+2.42%)

As of 07:14 PM Eastern

Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.

Nanobiotix NASDAQ:NBTX

$5.32 +0.10 (+1.92%)

As of 04:00 PM Eastern

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.

ProQR Therapeutics NASDAQ:PRQR

$2.40 +0.05 (+2.13%)

Closing price 04:00 PM Eastern

Extended Trading

$2.26 -0.15 (-6.04%)

As of 06:18 PM Eastern

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as various other targets. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center; Inserm Transfert SA; Ionis Pharmaceuticals, Inc.; Vico Therapeutics B.V.; University of Rochester; and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.

Acelyrin NASDAQ:SLRN

Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease. In addition, the company's develops SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. Acelyrin, Inc. was incorporated in 2020 and is headquartered in Agoura Hills, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time